<n-docbody><doc bill="Y"><content.metadata.block><cmd.identifiers><cmd.cites><cmd.second.line.cite><bop/><bos/>Multidistrict Lit Man § 5:50<eos/><eop/></cmd.second.line.cite></cmd.cites></cmd.identifiers></content.metadata.block><prop.block><prop.head toc-guid=""><bop/><bos/><headtext>Multidistrict Litigation Manual</headtext><eos/><eop/></prop.head><content.metadata.block><cmd.dates><cmd.currency.default iso.d="20190501"><bop/><bos/>May 2019 Update<eos/><eop/></cmd.currency.default></cmd.dates></content.metadata.block><author.line><bop/><bos/><author>David F. Herr[<footnote.reference refid="If4aa80f16b3e11e99b03e53d6dd36aa2">a0</footnote.reference>]</author><eos/><eop/></author.line><prop.head toc-guid="I97b7f560933b11da99e2b07024dacc26"><bop/><bos/><label.name>Part</label.name><label.designator>I.</label.designator><headtext>Handling Cases Before the Judicial Panel on Multidistrict Litigation</headtext><eos/><eop/></prop.head><prop.head toc-guid="Id8e3eb20933b11da99e2b07024dacc26"><bop/><bos/><label.name>Chapter</label.name><label.designator>5.</label.designator><headtext>Factors in Deciding Whether Transfer Is Appropriate</headtext><eos/><eop/></prop.head></prop.block><message.block><include.copyright n-include_collection="w_wlnv_msg" n-include_guid="I1DA35ED81DD211B281BAD200220BDFCA">Copyright (c) 2017 Thomson/RIA All rights reserved.</include.copyright></message.block><section><section.front><doc.title toc-guid="I94f32745e1e311da9c26e67ca3b71335"><head parent="doc.title"><bop/><bos/><label.name>§ </label.name><label.designator>5:50.</label.designator><headtext>Arguments rejected by the Panel—Possibility that transfer would cause additional filings</headtext><eos/><eop/></head></doc.title></section.front><section.body><para><bop/><bos/><paratext>The Panel has regularly rejected the argument that creating a centralized MDL docket will create an incentive for filing additional actions.[<eos/><bos/><footnote.reference refid="If4aacf106b3e11e99b03e53d6dd36aa2">1</footnote.reference>] The Panel sometimes rejects this argument without particular explanation; in other cases it explains that this concern can be addressed by the transferee judge presiding over the centralized proceedings.[<eos/><bos/><footnote.reference refid="If4aacf116b3e11e99b03e53d6dd36aa2">2</footnote.reference>]</paratext><eos/><eop/></para></section.body></section><author.footnotes><footnote ID="If4aa80f16b3e11e99b03e53d6dd36aa2"><label.designator>a0</label.designator><footnote.body><para><bop/><bos/><paratext>Maslon Edelman Borman &amp; Brand, LLP, Minneapolis, Minnesota.<eos/></paratext><eop/></para></footnote.body></footnote></author.footnotes><footnote.block><footnote ID="If4aacf106b3e11e99b03e53d6dd36aa2"><label.designator>1</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914052" w-serial-number="2041795490" w-seq-number="00001" w-ref-type="RP" w-pub-number="0007903" ID="I838d98316b3e11e99f73e2698c313519">In re Ethicon Physiomesh Flexible Composite Hernia Mesh Products Liability Litigation, 254 F. Supp. 3d 1381 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914052" w-serial-number="2036887277" w-seq-number="00002" w-ref-type="RP" w-pub-number="0007903" ID="I838d98336b3e11e99f73e2698c313519">In re Fluoroquinolone Products Liability Litigation, 122 F. Supp. 3d 1378 (J.P.M.L. 2015)</cite.query>; <cite.query w-src-number="0304914052" w-serial-number="2041795490" w-seq-number="00003" w-ref-type="RP" w-pub-number="0007903" ID="I838d98356b3e11e99f73e2698c313519">In re Ethicon Physiomesh Flexible Composite Hernia Mesh Products Liability Litigation, 254 F. Supp. 3d 1381 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914052" w-serial-number="2032764224" w-seq-number="00004" w-ref-type="RP" w-pub-number="0004637" ID="I838d98376b3e11e99f73e2698c313519">In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II), 997 F. Supp. 2d 1354 (J.P.M.L. 2014)</cite.query> (noting that transferee court can deal with any spurious claims); <cite.query w-src-number="0304914052" w-serial-number="2035757402" w-seq-number="00005" w-ref-type="RP" w-pub-number="0007903" ID="I838d98396b3e11e99f73e2698c313519">In re: Benicar (Olmesartan) Products Liability Litigation, 96 F. Supp. 3d 1381 (U.S.J.P.M.L. 2015)</cite.query>; <cite.query w-src-number="0304914052" w-serial-number="2034976305" w-seq-number="00006" w-ref-type="RP" w-pub-number="0007903" ID="I838d983b6b3e11e99f73e2698c313519">In re: Xarelto (Rivaroxaban) Products Liability Litigation, 65 F. Supp. 3d 1402 (U.S.J.P.M.L. 2014)</cite.query>; <cite.query w-src-number="0304914052" w-serial-number="2034645472" w-seq-number="00007" w-ref-type="RP" w-pub-number="0007903" ID="I838d983d6b3e11e99f73e2698c313519">In re: Cook Medical, Inc., IVC Filters Marketing, Sales Practices and Products Liability Litigation, 53 F. Supp. 3d 1379 (U.S.J.P.M.L. 2014)</cite.query>;<cite.query w-src-number="0304914052" w-serial-number="2009530979" w-seq-number="00008" w-ref-type="RP" w-pub-number="0004637" ID="I838d983f6b3e11e99f73e2698c313519">In re Seroquel Products Liability Litigation, 447 F. Supp. 2d 1376 (J.P.M.L. 2006)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4aacf116b3e11e99b03e53d6dd36aa2"><label.designator>2</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914052" w-serial-number="2035757402" w-seq-number="00009" w-ref-type="RP" w-pub-number="0007903" ID="I838e5b816b3e11e99f73e2698c313519">In re: Benicar (Olmesartan) Products Liability Litigation, 96 F. Supp. 3d 1381 (U.S.J.P.M.L. 2015)</cite.query>; <cite.query w-src-number="0304914052" w-serial-number="2034976305" w-seq-number="00010" w-ref-type="RP" w-pub-number="0007903" ID="I838e5b836b3e11e99f73e2698c313519">In re: Xarelto (Rivaroxaban) Products Liability Litigation, 65 F. Supp. 3d 1402 (U.S.J.P.M.L. 2014)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote></footnote.block><content.metadata.block><cmd.royalty><cmd.copyright><bop/><bos/>Westlaw. © 2019 Thomson Reuters.  <eos/><bos/>No Claim to Orig. U.S. Govt. <eos/><bos/>Works.<eos/><eop/></cmd.copyright></cmd.royalty><cmd.identifiers><cmd.cites><cmd.first.line.cite><bop/><bos/>MDLITMAN § 5:50<eos/><eop/></cmd.first.line.cite></cmd.cites></cmd.identifiers></content.metadata.block></doc></n-docbody>
